Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BFRI | PRESS-RELEASE | bullish | 7/10 | Biofrontera reported Q1 2026 revenue of $10.1M (+17% YoY), gross margins expanding to ~80% from ~62%, and near-zero cash | May 14, 2026 |
| CRMD | PRESS-RELEASE | bullish | 7/10 | CorMedix reported Q1 2026 revenue of $127.4M (21% above $105M consensus) and GAAP EPS of $0.43 diluted (30% above $0.33 | May 14, 2026 |
| HCWB | PRESS-RELEASE | bullish | 6/10 | HCW Biologics announced preclinical data showing its fusion immunotherapeutic HCW11-040 prevented bronchopulmonary dyspl | May 14, 2026 |
| INKT | PRESS-RELEASE | bullish | 7/10 | MiNK Therapeutics announced the initiation of a randomized Phase 2 trial (C-1300-02) evaluating its off-the-shelf iNKT c | May 14, 2026 |
| CGTX | PRESS-RELEASE | neutral | 3/10 | Cognition Therapeutics announced a second philanthropic donation to extend its expanded access program (EAP) for zervime | May 14, 2026 |
| IXHL | 8-K | bullish | 5/10 | Incannex Healthcare announced the official commencement of its DReAMzz clinical study for IHL-42X in obstructive sleep a | May 14, 2026 |
| BAK | 6-K | bearish | 7/10 | Braskem reported Q1 2026 Recurring EBITDA of US$192 million, up 76% QoQ, driven by a US$32 million REIQ tax credit benef | May 14, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced positive Phase III VOLGA trial results showing that perioperative Imfinzi (durvalumab) plus neoadj | May 14, 2026 |
| GHRS | 6-K | neutral | 5/10 | GH Research PLC reported Q1 2026 financial results showing a net loss of $19.0 million ($0.31 per share), compared to a | May 14, 2026 |
| CLRB | 8-K | mixed | 7/10 | Cellectar Biosciences reported Q1 2026 net loss of $5.7M ($1.33/share), narrower than the $6.6M loss ($4.30/share) in Q1 | May 14, 2026 |
| CLRB | PRESS-RELEASE | bullish | 6/10 | Cellectar Biosciences reported Q1 2026 EPS of -$1.33, beating the -$1.89 consensus, but remains pre-revenue. The key cat | May 14, 2026 |
| RGNX | 8-K | mixed | 7/10 | REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a year ago, as revenu | May 14, 2026 |
| IVVD | 8-K | mixed | 6/10 | Invivyd reported Q1 2026 PEMGARDA net product revenue of $13.7M (+22% YoY), but net loss widened to $41.4M from $16.3M a | May 14, 2026 |
| CYPH | 8-K | bearish | 6/10 | Cypherpunk Technologies reported Q1 2026 results with a net loss of $77.2M driven by a $77.6M unrealized mark-to-market | May 14, 2026 |
| CABA | 8-K | bullish | 7/10 | Cabaletta Bio presented new clinical data at ASGCT 2026 showing that 2 of 4 refractory pemphigus vulgaris patients achie | May 14, 2026 |
| XRTX | PRESS-RELEASE | bearish | 6/10 | XORTX Therapeutics priced a public offering of ~2.66M shares at $1.88/share for $5M gross proceeds, representing massive | May 14, 2026 |
| CRVS | 8-K | bullish | 7/10 | Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, sho | May 14, 2026 |
| TLSA | 6-K | bullish | 7/10 | Tiziana Life Sciences reported initial quantitative PET imaging results from the first two patients with Multiple System | May 14, 2026 |
| PTHS | 8-K | neutral | 5/10 | Pelthos Therapeutics reported Q1 2026 revenue of $10.9M (product revenue $10.7M, up 17% QoQ from $9.1M) and a GAAP net l | May 14, 2026 |
| CABA | 8-K | bearish | 6/10 | Cabaletta Bio reported Q1 2026 net loss of $43.5M (EPS -$0.39, beating consensus of -$0.41 by ~5%) with cash of $116.6M, | May 14, 2026 |
| CABA | PRESS-RELEASE | neutral | 4/10 | Cabaletta Bio reported Q1 2026 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39, with no revenue. The miss is marginal | May 14, 2026 |
| LRMR | 8-K | bullish | 7/10 | Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29.3M loss in Q1 2025, | May 14, 2026 |
| LRMR | PRESS-RELEASE | bullish | 7/10 | Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company | May 14, 2026 |
| PYXS | PRESS-RELEASE | neutral | 4/10 | Pyxis Oncology reported Q1 2026 EPS of -$0.37, missing consensus of -$0.35 by 5.7%. The clinical-stage biotech has $42.5 | May 14, 2026 |
| HYPD | PRESS-RELEASE | mixed | 6/10 | Hyperion DeFi reported Q1 2026 GAAP net income of $8.8M vs a net loss of $3.5M in Q1 2025, driven by $21.5M in treasury | May 14, 2026 |
| PTHS | PRESS-RELEASE | neutral | 5/10 | Pelthos Therapeutics reported Q1 2026 EPS of -$3.09, beating the -$3.58 consensus by 13.7%, on total revenue of $10.9M ( | May 14, 2026 |
| IVVD | PRESS-RELEASE | neutral | 5/10 | Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $ | May 14, 2026 |
| GHRS | PRESS-RELEASE | mixed | 6/10 | GH Research reported Q1 2026 EPS of -$0.31, wider than the -$0.26 consensus estimate (a ~19% miss on a GAAP basis), and | May 14, 2026 |
| AUTL | PRESS-RELEASE | mixed | 6/10 | Autolus reported Q1 2026 AUCATZYL net product revenue of $26.2M (vs $9.0M YoY), achieving its first positive gross margi | May 14, 2026 |
| NRXP | PRESS-RELEASE | neutral | 1/10 | NRx Pharmaceuticals, Inc. announced it will report its Q1 2026 results on May 18, 2026. | May 14, 2026 |